Indivior Pharmaceuticals (INDV) Tax Provisions (2024 - 2026)

Indivior Pharmaceuticals has reported Tax Provisions for 3 years, with the latest figure at $38.0 million in Q2 2026.

• On a quarterly basis, Tax Provisions fell 13.64% year-over-year to $38.0 million in Q2 2026; TTM through Jun 2026 was $38.0 million, a 52.5% decrease from a year earlier, with the FY2025 full-year figure at $29.0 million, up 123.08% from the prior year.
• Tax Provisions was $38.0 million for Q2 2026 at Indivior Pharmaceuticals, up from $26.0 million in the prior quarter.
• The five-year high for Tax Provisions was $44.0 million in Q2 2025, with the low at -$23.0 million in Q2 2024.
• Average Tax Provisions over 3 years is $10.6 million, with a median of $11.0 million recorded in 2024.
• The largest YoY upside for Tax Provisions was 291.3% in 2025 against a maximum downside of 223.53% in 2025.
• Over 3 years, Tax Provisions stood at $17.0 million in 2024, then tumbled by 223.53% to -$21.0 million in 2025, then jumped by 280.95% to $38.0 million in 2026.
• The last three Tax Provisions figures came in at $38.0 million (Q2 2026), $26.0 million (Q1 2026), and -$21.0 million (Q4 2025), per Business Quant data.